ethyl 8-fluoro-1-(2-hydroxyethyl)-6-iodo-4-oxo-1,4-dihydro-3-quinoline carboxylate | 936625-05-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: ethyl 8-fluoro-1-(2-hydroxyethyl)-6-iodo-4-oxo-1,4-dihydro-3-quinoline carboxylate
• 英文别名: ethyl 8-fluoro-1-(2-hydroxyethyl)-6-iodo-4-oxo-1,4-dihydroquinoline-3-carboxylate；ethyl 8-fluoro-1-(2-hydroxyethyl)-6-iodo-4-oxoquinoline-3-carboxylate
• CAS: 936625-05-7
• 化学式: C₁₄H₁₃FINO₄
• 分子量: 405.164
• InChiKey: IRDDLAOTQYQGJF-UHFFFAOYSA-N

物化性质

• 沸点：
  490.1±45.0 °C(Predicted)
• 密度：
  1.757±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  21
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  66.8
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  ethyl 8-fluoro-1-(2-hydroxyethyl)-6-iodo-4-oxo-1,4-dihydro-3-quinoline carboxylate 在 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 24.0h， 以18%的产率得到ethyl 9-iodo-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylate
  参考文献：
  名称：

  [EN] HETEROCYCLIC UREA DERIVATIVES FOR THE TREATMENT OF BACTERIAL INFECTIONS
  [FR] DÉRIVÉS HÉTÉROCYCLIQUES D'URÉE POUR LE TRAITEMENT D'INFECTIONS BACTÉRIENNES

  摘要：

  描述了化学式（I）的化合物及其药用盐。还描述了它们的制备过程、含有它们的药物组成、它们作为药物的用途以及它们在治疗细菌感染中的用途。

  公开号：

  WO2009147433A1
• 作为产物：
  描述：

  2-氟-4-碘苯胺 在 Eaton's reagent 、 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 128.0h， 生成 ethyl 8-fluoro-1-(2-hydroxyethyl)-6-iodo-4-oxo-1,4-dihydro-3-quinoline carboxylate
  参考文献：
  名称：

  [EN] HETEROCYCLIC UREA DERIVATIVES FOR THE TREATMENT OF BACTERIAL INFECTIONS
  [FR] DÉRIVÉS HÉTÉROCYCLIQUES D'URÉE POUR LE TRAITEMENT D'INFECTIONS BACTÉRIENNES

  摘要：

  描述了化学式（I）的化合物及其药用盐。还描述了它们的制备过程、含有它们的药物组成、它们作为药物的用途以及它们在治疗细菌感染中的用途。

  公开号：

  WO2009147433A1

文献信息

• HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF
  申请人：Choy Allison Laura

  公开号：US20100190745A1

  公开（公告）日：2010-07-29

  Compounds of formula (I) and their pharmaceutically acceptable salts are described. Processes for their preparation, pharmaceutical compositions containing them, their use as medicaments and their use in the treatment of bacterial infections are also described.

  描述了式(I)的化合物及其药学上可接受的盐。还描述了它们的制备过程、含有它们的制药组合物、它们作为药物的使用以及它们在治疗细菌感染方面的使用。
• Heterocyclic urea derivatives and methods of use thereof
  申请人：AstraZeneca AB

  公开号：US08283361B2

  公开（公告）日：2012-10-09

  Compounds of formula (I) and their pharmaceutically acceptable salts are described. Processes for their preparation, pharmaceutical compositions containing them, their use as medicaments and their use in the treatment of bacterial infections are also described.

  本文描述了公式(I)的化合物及其药学上可接受的盐。还描述了制备它们的过程，含有它们的制药组合物，它们作为药物的用途以及它们在治疗细菌感染方面的用途。
• MACROLONES
  申请人：Alihodzic Sulejman

  公开号：US20090170791A1

  公开（公告）日：2009-07-02

  A compound of formula (I) or a pharmaceutically acceptable derivative thereof, having antimicrobial activity, processes for their preparation, compositions containing them and to their use in medicine.

  具有抗微生物活性的化合物式（I）或其药学上可接受的衍生物，制备它们的方法，包含它们的组合物以及它们在医学上的使用。
• Quinolone Carboxylic Acids as a Novel Monoketo Acid Class of Human Immunodeficiency Virus Type 1 Integrase Inhibitors
  作者：Motohide Sato、Hiroshi Kawakami、Takahisa Motomura、Hisateru Aramaki、Takashi Matsuda、Masaki Yamashita、Yoshiharu Ito、Yuji Matsuzaki、Kazunobu Yamataka、Satoru Ikeda、Hisashi Shinkai

  DOI：10.1021/jm900460z

  日期：2009.8.13

  Human immunodeficiency virus type 1 (HIV-1) integrase is a crucial target for antiretroviral drugs, and several keto-enol acid class (often referred to as diketo acid class) inhibitors have clinically exhibited marked antiretroviral activity. Here, we show the synthesis and the detailed structure-activity relationship of the quinolone carboxylic acids as a novel monoketo acid class of integrase inhibitors. 6-(3-Chloro-2-fluorobenzyl)- 1-((2,S)-1-hydroxy-3,3-dimethylbutan-2-yl)-7-methoxy-4-oxo- 1,4-dihydroquinoline-3-carboxylic acid 51, which showed an IC50 of 5.8 nM in the strand transfer assay and an ED50 of 0.6 nM in the antiviral assay, and 6-(3-chloro-2-fluorobenzyl)-1-((2S)-1-hydroxy-3-methylbutan-2-yl)-7-methoxy-4-oxo-4-dihydroquinoline-3-carboxylic acid 49, which had an IC50 of 7.2 nM and an ED50 of 0.9 nM, were the most potent compounds in this class. The monoketo acid 49 was much more potent at inhibiting integrase-catalyzed strand transfer processes than 3'-processing reactions, as is the case with the keto-enol acids. Elvitegravir 49 was chosen as a candidate for further studies and is currently in phase 3 clinical trials.
• WO2007/54296
  申请人：——

  公开号：——

  公开（公告）日：——